CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study-Reference-Cited by-同舟云学术

CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study

Published:2018-02-01 Issue:1 Volume:17 Page:
ISSN:1475-2875
Container-title:Malaria Journal
language:en
Short-container-title:Malar J

Author:

Brasil Larissa W.,Rodrigues-Soares Fernanda,Santoro Ana B.,Almeida Anne C. G.,Kühn Andrea,Ramasawmy Rajendranath,Lacerda Marcus V. G.,Monteiro Wuelton M.,Suarez-Kurtz Guilherme

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

FAPEAM

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Parasitology

Link

http://link.springer.com/content/pdf/10.1186/s12936-017-2139-7.pdf

Reference26 articles.

1. WHO. World Malaria Report. Geneva: World Health Organization; 2016. http://www.who.int/malaria/publications/world-malaria-report-2016/en/ . Accessed 20 Oct 2017.

2. Gil JP. Malaria pharmacogenomics: return to the future. Pharmacogenomics. 2013;14:707–10.

3. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164:469–80.

4. Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol. 2014;10:769–85.

5. Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther. 2016;161:1–10.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study);PLOS Neglected Tropical Diseases;2024-06-05

2. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study;The Lancet Infectious Diseases;2024-06

3. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis;Malaria Journal;2023-10-10

4. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment;International Journal of Infectious Diseases;2023-05

5. Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure;Frontiers in Pharmacology;2022-11-15